Home
/
Unicycive Therapeutics, Inc.
/
Financials
/
Quarterly
Unicycive Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Unicycive Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2023
$675.0K
Nov 13, 2024
Q2
2024
Jun 30, 2023
$675.0K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$675.0K
May 13, 2024
Q3
2023
Sep 30, 2022
$951.0K
Nov 14, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($6.01M)
Nov 12, 2025
Q3
2025
Jun 30, 2025
($6.45M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($6.45M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
$570.0K
May 14, 2025
Q2
2025
Mar 31, 2025
$570.0K
Aug 14, 2025
Q3
2025
Mar 31, 2025
$570.0K
Nov 12, 2025
Q3
2025
Sep 30, 2024
($4.10M)
Nov 12, 2025
Q3
2025
Jun 30, 2024
$9.86M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$9.86M
Aug 14, 2025
Q2
2025
Mar 31, 2024
($20.96M)
Aug 14, 2025
Q3
2025
Mar 31, 2024
($20.96M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($20.96M)
May 14, 2025
Q3
2024
Sep 30, 2023
($4.33M)
Nov 13, 2024
Q3
2024
Jun 30, 2023
($3.84M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($3.84M)
Aug 14, 2024
Q2
2024
Mar 31, 2023
($14.58M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($14.58M)
May 13, 2024
Q3
2024
Mar 31, 2023
($14.58M)
Nov 13, 2024
Q3
2023
Sep 30, 2022
($5.56M)
Nov 14, 2023
Q3
2023
Jun 30, 2022
($3.64M)
Nov 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.34M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($6.96M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($7.99M)
May 14, 2025
Q3
2025
Sep 30, 2024
($6.25M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($7.40M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($9.20M)
May 14, 2025
Q3
2024
Sep 30, 2023
($5.94M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($4.32M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($4.20M)
May 13, 2024
Q3
2023
Sep 30, 2022
($5.55M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($3.64M)
Aug 14, 2023
Q1
2022
Mar 31, 2022
($3.54M)
May 12, 2022
Q3
2022
Sep 30, 2021
($4.72M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($779.0K)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($731.0K)
May 12, 2022
Q3
2021
Sep 30, 2020
($626.0K)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($336.0K)
Aug 16, 2021